Recovering What Matters: High Protein Recovery after Endotoxin Removal from LPS-Contaminated Formulations Using Novel...

Area of Science:

• Biotechnology
• Immunology
• Pharmaceutical Science

Background:

• Endotoxins, or lipopolysaccharides (LPS), are components of Gram-negative bacteria that can cause severe immune responses.
• Regulatory agencies mandate strict limits for endotoxin levels in injectable pharmaceuticals.
• Current endotoxin removal methods rely on non-specific adsorption, often leading to loss of valuable proteins.

Purpose of the Study:

• To develop a novel method for selective endotoxin removal using antibody-conjugated microparticles.
• To evaluate the efficacy and specificity of anti-Lipid A microparticles in endotoxin depletion.
• To compare the performance of specific anti-Lipid A particles against non-specific removal systems in complex formulations.

Main Methods:

• Microparticles were conjugated with anti-Lipid A antibodies.
• Flow cytometry and microscopy were used for particle characterization.
• Endotoxin depletion capacity was quantified using Limulus Amebocyte Lysate test and nanoparticle tracking analysis.
• Comparative studies were conducted using formulations with varying complexity (proteins, buffers, extracts).

Main Results:

• Anti-Lipid A microparticles demonstrated a high endotoxin depletion capacity (> 6 × 10^3 EU/mg).
• Specific particles achieved superior protein recovery compared to non-specific methods across different formulations.
• Endotoxin removal efficiency was maintained even in complex biological mixtures.

Conclusions:

• Antibody-mediated specificity offers an advantage for endotoxin removal in pharmaceutical applications.
• The developed anti-Lipid A microparticles provide an effective and selective strategy for endotoxin decontamination.
• This approach has the potential to significantly improve product yield and purity in biopharmaceutical manufacturing.